Tag: global catheter related bloodstream infection market size

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Catheter-Related Bloodstream Infection Market Expansion From $1.71 Billion In 2026 To $2.1 Billion In 2030

The market for catheter-related bloodstream infection solutions experienced robust expansion recently, projecting a rise from $1.62 billion in 2025 to $1.71 billion in 2026, reflecting a compound annual growth rate of 6.0%. Key factors driving this historical growth trajectory include a greater reliance on central venous catheters, an escalating prevalence of infections acquired within healthcare settings, the implementation of antibiotic lock therapy, the proliferation of intensive care units, and heightened clinical consciousness regarding catheter-related bloodstream infections.

The market for catheter-related bloodstream infections is poised for significant expansion in the upcoming years, projected to reach a value of $2.11 billion by 2030, driven by a compound annual growth rate of 5.3%. This anticipated growth throughout the forecast period stems from several key factors, including heightened investments in infection prevention strategies, an escalating need for effective antimicrobial resistance management, the broadening of hospital infection control initiatives, a greater uptake of combined therapeutic approaches, and advancements in diagnostic tool development. During this same period, prominent market trends are expected to include a more widespread utilization of sophisticated antimicrobial lock solutions, increased implementation of infection surveillance programs, a stronger emphasis on preventing hospital-acquired infections, the expanded application of combination antimicrobial treatments, and a more concentrated effort on early detection and timely intervention.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16646&type=smp

Catheter-Related Bloodstream Infection Market Expansion Supported By Key Demand Factors

The increasing incidence of infections acquired in hospital settings is anticipated to fuel the expansion of the market for catheter-related bloodstream infections. Infections contracted within healthcare facilities, often appearing 48 hours or more post-admission, stem from factors including the rise of resistant microbes, insufficient infection control practices, and patient vulnerabilities. Given their invasive nature and propensity for microbial growth, catheter-related bloodstream infections represent a substantial portion of these hospital-acquired infections, especially for individuals with inserted catheters. Illustrating this point, data from September 2025, sourced from the National Library of Medicine, indicates that in 2024, antimicrobial-resistant organisms constituted 6.6% of infections, with approximately one-third of healthcare-associated infections being linked to medical devices, and the occurrence of central line-associated bloodstream infections doubling to 0.4%. Consequently, the escalating rate of hospital-acquired infections is poised to stimulate market growth in the catheter-related bloodstream infection sector.

An upswing in spending on healthcare services is foreseen to be a significant catalyst for the expansion of the catheter-related bloodstream infection market. This refers to the aggregate financial investment in safeguarding, curing, and overseeing health issues by various entities. Such increased spending is largely a consequence of medical advancements, as novel diagnostic equipment, therapeutic interventions, and cutting-edge treatments frequently incur substantial costs, leading to a broader financial outlay in healthcare. Enhanced healthcare spending contributes to mitigating catheter-related bloodstream infections by allocating resources towards preventative strategies, professional development, surveillance mechanisms, and prompt medical care, thereby ultimately enhancing patient results and reducing long-term expenses. To illustrate, information released in December 2024 by the Centers for Medicare & Medicaid Services highlights that in 2023, healthcare spending in the United States rose by 7.5%, reaching $4.9 trillion, equating to approximately $14,570 per person. Therefore, the augmenting levels of healthcare expenditure are actively propelling the growth trajectory of the catheter-related bloodstream infection market.

Catheter-Related Bloodstream Infection Market Segment Analysis: What Are The Major Market Categories?

The catheter-related bloodstream infection market covered in this report is segmented –

1) By Treatment: Antibiotic Lock Therapy, Anti-Microbial Agents

2) By Source Of Infection Or Causative Agents: Staphylococcus Aureus, Acinetobacter Baumannii, Escherichia Coli (E. Coli), Klebsiella Pneumoniae (K. Pneumonia), Candida Species (Candida Sp.), Pseudomonas Aeruginosa (P. Aeruginosa), Other Source Of Infection Or Causative Agents

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Antibiotic Lock Therapy: Catheter Lock Solutions (Antibiotic-based), Combination Antibiotic Lock Therapy

2) By Anti-Microbial Agents: Antibiotics, Antifungal Agents, Antiseptic Agents

Catheter-Related Bloodstream Infection Market Growth Trends Influencing Competitive Dynamics

Pioneering firms within the catheter-related bloodstream infection sector are actively creating novel catheter lock mechanisms aimed at bolstering infection control and elevating patient well-being; these lock solutions are liquids introduced into a catheter to safeguard against infections and preserve its unobstructed state between administrations. A prime illustration of this innovation is CorMedix Inc., a US-based biopharmaceutical entity dedicated to therapeutic product development and marketing, which secured crucial US Food and Drug Administration endorsement in November 2023 for DefenCath. This particular catheter lock solution, a synergistic blend of taurolidine and heparin, is now accessible for adult patients experiencing kidney failure and undergoing ongoing hemodialysis through a central venous catheter (CVC). The antimicrobial and antifungal formulation is engineered specifically to mitigate catheter-related bloodstream infections (CRBSIs), effectively integrating heparin’s anticoagulant benefits with taurolidine’s extensive antibacterial and antifungal efficacy.

Catheter-Related Bloodstream Infection Market Leading Companies Driving Competitive Growth

Major companies operating in the catheter-related bloodstream infection market are Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, 3M Company, Eli Lilly and Company, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company, Viatris Inc., B. Braun Medical Inc., Aurobindo Pharma Limited, Lupin Ltd., Xellia Pharmaceuticals Ltd., SteriMax Inc., Bactiguard AB, Hetero Healthcare Ltd., TauroPharm GmbH, Advacare Pharma, Citus Pharmaceuticals Inc., CorMedix Inc., JoinHub Pharma LLP, IntegraDose Compounding Services LLC

Access The Complete Catheter-Related Bloodstream Infection Market Report:

https://www.thebusinessresearchcompany.com/report/catheter-related-bloodstream-infection-global-market-report

Catheter-Related Bloodstream Infection Market Largest Region By Revenue And Market Share

North Americawas the largest region in the catheter-related bloodstream infection market in 2025. The regions covered in the catheter-related bloodstream infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Catheter-Related Bloodstream Infection Market Expansion From $1.71 Billion In 2026 To $2.1 Billion In 2030

The market for catheter-related bloodstream infection solutions experienced robust expansion recently, projecting a rise from $1.62 billion in 2025 to $1.71 billion in 2026, reflecting a compound annual growth rate of 6.0%. Key factors driving this historical growth trajectory include a greater reliance on central venous catheters, an escalating prevalence of infections acquired within healthcare settings, the implementation of antibiotic lock therapy, the proliferation of intensive care units, and heightened clinical consciousness regarding catheter-related bloodstream infections.

The market for catheter-related bloodstream infections is poised for significant expansion in the upcoming years, projected to reach a value of $2.11 billion by 2030, driven by a compound annual growth rate of 5.3%. This anticipated growth throughout the forecast period stems from several key factors, including heightened investments in infection prevention strategies, an escalating need for effective antimicrobial resistance management, the broadening of hospital infection control initiatives, a greater uptake of combined therapeutic approaches, and advancements in diagnostic tool development. During this same period, prominent market trends are expected to include a more widespread utilization of sophisticated antimicrobial lock solutions, increased implementation of infection surveillance programs, a stronger emphasis on preventing hospital-acquired infections, the expanded application of combination antimicrobial treatments, and a more concentrated effort on early detection and timely intervention.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16646&type=smp

Catheter-Related Bloodstream Infection Market Expansion Supported By Key Demand Factors

The increasing incidence of infections acquired in hospital settings is anticipated to fuel the expansion of the market for catheter-related bloodstream infections. Infections contracted within healthcare facilities, often appearing 48 hours or more post-admission, stem from factors including the rise of resistant microbes, insufficient infection control practices, and patient vulnerabilities. Given their invasive nature and propensity for microbial growth, catheter-related bloodstream infections represent a substantial portion of these hospital-acquired infections, especially for individuals with inserted catheters. Illustrating this point, data from September 2025, sourced from the National Library of Medicine, indicates that in 2024, antimicrobial-resistant organisms constituted 6.6% of infections, with approximately one-third of healthcare-associated infections being linked to medical devices, and the occurrence of central line-associated bloodstream infections doubling to 0.4%. Consequently, the escalating rate of hospital-acquired infections is poised to stimulate market growth in the catheter-related bloodstream infection sector.

An upswing in spending on healthcare services is foreseen to be a significant catalyst for the expansion of the catheter-related bloodstream infection market. This refers to the aggregate financial investment in safeguarding, curing, and overseeing health issues by various entities. Such increased spending is largely a consequence of medical advancements, as novel diagnostic equipment, therapeutic interventions, and cutting-edge treatments frequently incur substantial costs, leading to a broader financial outlay in healthcare. Enhanced healthcare spending contributes to mitigating catheter-related bloodstream infections by allocating resources towards preventative strategies, professional development, surveillance mechanisms, and prompt medical care, thereby ultimately enhancing patient results and reducing long-term expenses. To illustrate, information released in December 2024 by the Centers for Medicare & Medicaid Services highlights that in 2023, healthcare spending in the United States rose by 7.5%, reaching $4.9 trillion, equating to approximately $14,570 per person. Therefore, the augmenting levels of healthcare expenditure are actively propelling the growth trajectory of the catheter-related bloodstream infection market.

Catheter-Related Bloodstream Infection Market Segment Analysis: What Are The Major Market Categories?

The catheter-related bloodstream infection market covered in this report is segmented –

1) By Treatment: Antibiotic Lock Therapy, Anti-Microbial Agents

2) By Source Of Infection Or Causative Agents: Staphylococcus Aureus, Acinetobacter Baumannii, Escherichia Coli (E. Coli), Klebsiella Pneumoniae (K. Pneumonia), Candida Species (Candida Sp.), Pseudomonas Aeruginosa (P. Aeruginosa), Other Source Of Infection Or Causative Agents

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Antibiotic Lock Therapy: Catheter Lock Solutions (Antibiotic-based), Combination Antibiotic Lock Therapy

2) By Anti-Microbial Agents: Antibiotics, Antifungal Agents, Antiseptic Agents

Catheter-Related Bloodstream Infection Market Growth Trends Influencing Competitive Dynamics

Pioneering firms within the catheter-related bloodstream infection sector are actively creating novel catheter lock mechanisms aimed at bolstering infection control and elevating patient well-being; these lock solutions are liquids introduced into a catheter to safeguard against infections and preserve its unobstructed state between administrations. A prime illustration of this innovation is CorMedix Inc., a US-based biopharmaceutical entity dedicated to therapeutic product development and marketing, which secured crucial US Food and Drug Administration endorsement in November 2023 for DefenCath. This particular catheter lock solution, a synergistic blend of taurolidine and heparin, is now accessible for adult patients experiencing kidney failure and undergoing ongoing hemodialysis through a central venous catheter (CVC). The antimicrobial and antifungal formulation is engineered specifically to mitigate catheter-related bloodstream infections (CRBSIs), effectively integrating heparin’s anticoagulant benefits with taurolidine’s extensive antibacterial and antifungal efficacy.

Catheter-Related Bloodstream Infection Market Leading Companies Driving Competitive Growth

Major companies operating in the catheter-related bloodstream infection market are Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, 3M Company, Eli Lilly and Company, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company, Viatris Inc., B. Braun Medical Inc., Aurobindo Pharma Limited, Lupin Ltd., Xellia Pharmaceuticals Ltd., SteriMax Inc., Bactiguard AB, Hetero Healthcare Ltd., TauroPharm GmbH, Advacare Pharma, Citus Pharmaceuticals Inc., CorMedix Inc., JoinHub Pharma LLP, IntegraDose Compounding Services LLC

Access The Complete Catheter-Related Bloodstream Infection Market Report:

https://www.thebusinessresearchcompany.com/report/catheter-related-bloodstream-infection-global-market-report

Catheter-Related Bloodstream Infection Market Largest Region By Revenue And Market Share

North Americawas the largest region in the catheter-related bloodstream infection market in 2025. The regions covered in the catheter-related bloodstream infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Catheter-Related Bloodstream Infection Market Expansion From $1.71 Billion In 2026 To $2.1 Billion In 2030

The market for catheter-related bloodstream infection solutions experienced robust expansion recently, projecting a rise from $1.62 billion in 2025 to $1.71 billion in 2026, reflecting a compound annual growth rate of 6.0%. Key factors driving this historical growth trajectory include a greater reliance on central venous catheters, an escalating prevalence of infections acquired within healthcare settings, the implementation of antibiotic lock therapy, the proliferation of intensive care units, and heightened clinical consciousness regarding catheter-related bloodstream infections.

The market for catheter-related bloodstream infections is poised for significant expansion in the upcoming years, projected to reach a value of $2.11 billion by 2030, driven by a compound annual growth rate of 5.3%. This anticipated growth throughout the forecast period stems from several key factors, including heightened investments in infection prevention strategies, an escalating need for effective antimicrobial resistance management, the broadening of hospital infection control initiatives, a greater uptake of combined therapeutic approaches, and advancements in diagnostic tool development. During this same period, prominent market trends are expected to include a more widespread utilization of sophisticated antimicrobial lock solutions, increased implementation of infection surveillance programs, a stronger emphasis on preventing hospital-acquired infections, the expanded application of combination antimicrobial treatments, and a more concentrated effort on early detection and timely intervention.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16646&type=smp

Catheter-Related Bloodstream Infection Market Expansion Supported By Key Demand Factors

The increasing incidence of infections acquired in hospital settings is anticipated to fuel the expansion of the market for catheter-related bloodstream infections. Infections contracted within healthcare facilities, often appearing 48 hours or more post-admission, stem from factors including the rise of resistant microbes, insufficient infection control practices, and patient vulnerabilities. Given their invasive nature and propensity for microbial growth, catheter-related bloodstream infections represent a substantial portion of these hospital-acquired infections, especially for individuals with inserted catheters. Illustrating this point, data from September 2025, sourced from the National Library of Medicine, indicates that in 2024, antimicrobial-resistant organisms constituted 6.6% of infections, with approximately one-third of healthcare-associated infections being linked to medical devices, and the occurrence of central line-associated bloodstream infections doubling to 0.4%. Consequently, the escalating rate of hospital-acquired infections is poised to stimulate market growth in the catheter-related bloodstream infection sector.

An upswing in spending on healthcare services is foreseen to be a significant catalyst for the expansion of the catheter-related bloodstream infection market. This refers to the aggregate financial investment in safeguarding, curing, and overseeing health issues by various entities. Such increased spending is largely a consequence of medical advancements, as novel diagnostic equipment, therapeutic interventions, and cutting-edge treatments frequently incur substantial costs, leading to a broader financial outlay in healthcare. Enhanced healthcare spending contributes to mitigating catheter-related bloodstream infections by allocating resources towards preventative strategies, professional development, surveillance mechanisms, and prompt medical care, thereby ultimately enhancing patient results and reducing long-term expenses. To illustrate, information released in December 2024 by the Centers for Medicare & Medicaid Services highlights that in 2023, healthcare spending in the United States rose by 7.5%, reaching $4.9 trillion, equating to approximately $14,570 per person. Therefore, the augmenting levels of healthcare expenditure are actively propelling the growth trajectory of the catheter-related bloodstream infection market.

Catheter-Related Bloodstream Infection Market Segment Analysis: What Are The Major Market Categories?

The catheter-related bloodstream infection market covered in this report is segmented –

1) By Treatment: Antibiotic Lock Therapy, Anti-Microbial Agents

2) By Source Of Infection Or Causative Agents: Staphylococcus Aureus, Acinetobacter Baumannii, Escherichia Coli (E. Coli), Klebsiella Pneumoniae (K. Pneumonia), Candida Species (Candida Sp.), Pseudomonas Aeruginosa (P. Aeruginosa), Other Source Of Infection Or Causative Agents

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Antibiotic Lock Therapy: Catheter Lock Solutions (Antibiotic-based), Combination Antibiotic Lock Therapy

2) By Anti-Microbial Agents: Antibiotics, Antifungal Agents, Antiseptic Agents

Catheter-Related Bloodstream Infection Market Growth Trends Influencing Competitive Dynamics

Pioneering firms within the catheter-related bloodstream infection sector are actively creating novel catheter lock mechanisms aimed at bolstering infection control and elevating patient well-being; these lock solutions are liquids introduced into a catheter to safeguard against infections and preserve its unobstructed state between administrations. A prime illustration of this innovation is CorMedix Inc., a US-based biopharmaceutical entity dedicated to therapeutic product development and marketing, which secured crucial US Food and Drug Administration endorsement in November 2023 for DefenCath. This particular catheter lock solution, a synergistic blend of taurolidine and heparin, is now accessible for adult patients experiencing kidney failure and undergoing ongoing hemodialysis through a central venous catheter (CVC). The antimicrobial and antifungal formulation is engineered specifically to mitigate catheter-related bloodstream infections (CRBSIs), effectively integrating heparin’s anticoagulant benefits with taurolidine’s extensive antibacterial and antifungal efficacy.

Catheter-Related Bloodstream Infection Market Leading Companies Driving Competitive Growth

Major companies operating in the catheter-related bloodstream infection market are Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, 3M Company, Eli Lilly and Company, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company, Viatris Inc., B. Braun Medical Inc., Aurobindo Pharma Limited, Lupin Ltd., Xellia Pharmaceuticals Ltd., SteriMax Inc., Bactiguard AB, Hetero Healthcare Ltd., TauroPharm GmbH, Advacare Pharma, Citus Pharmaceuticals Inc., CorMedix Inc., JoinHub Pharma LLP, IntegraDose Compounding Services LLC

Access The Complete Catheter-Related Bloodstream Infection Market Report:

https://www.thebusinessresearchcompany.com/report/catheter-related-bloodstream-infection-global-market-report

Catheter-Related Bloodstream Infection Market Largest Region By Revenue And Market Share

North Americawas the largest region in the catheter-related bloodstream infection market in 2025. The regions covered in the catheter-related bloodstream infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Catheter-Related Bloodstream Infection Market Grow Between 2026 And 2030?

The catheter-related bloodstream infection market has seen substantial growth in recent years. It is anticipated to expand from $1.62 billion in 2025 to $1.71 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.0%. This market’s past expansion can be attributed to the increased deployment of central venous catheters, a growing prevalence of hospital-acquired infections, the implementation of antibiotic lock therapy, the enlargement of intensive care facilities, and enhanced clinical understanding of crbsi.

The catheter-related bloodstream infection market size is projected to experience robust expansion in the coming years. This market is set to reach $2.11 billion in 2030, growing at a compound annual growth rate (CAGR) of 5.3%. The forecasted growth can be attributed to various factors such as increasing investments in infection prevention protocols, a rising demand for antimicrobial resistance management, the expansion of hospital infection control programs, a growing adoption of combination therapies, and advancements in diagnostic technologies. Significant trends within the forecast period include a greater use of advanced antimicrobial lock solutions, increasing adoption of infection surveillance programs, a heightened focus on preventing hospital-acquired infections, the proliferation of combination antimicrobial therapies, and an enhanced emphasis on early diagnosis and intervention.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/catheter-related-bloodstream-infection-global-market-report

Which Factors Are Influencing The Growth Of The Catheter-Related Bloodstream Infection Market?

The increasing occurrence of hospital-acquired infections is anticipated to boost the expansion of the catheter-related bloodstream infection market. HAIs are infections contracted by patients in healthcare settings while receiving treatment for other ailments, typically emerging 48 hours or more after admission. Factors like antimicrobial resistance, insufficient infection control, and patient vulnerability contribute to the rise in these infections. Catheter-related bloodstream infections are a major component of HAIs because of their invasive nature and potential for microbial growth, presenting risks to individuals with catheters. For example, the National Library of Medicine reported in September 2025 that in 2024, antimicrobial-resistant organisms constituted 6.6% of infections. Approximately one-third of healthcare-associated infections were associated with medical devices, and the incidence of central line-associated bloodstream infections surged to 0.4%. Consequently, the increasing incidence of hospital-acquired infections will fuel the growth of the catheter-related bloodstream infection market. The expansion of the catheter-related bloodstream infection market is anticipated to be driven by increasing healthcare expenditure. Healthcare expenditure signifies the total financial investment made by individuals, organizations, or governments towards the prevention, treatment, and management of health conditions. This spending is growing due to progress in medical technology, where advanced diagnostic tools, treatments, and innovative therapies often entail higher expenses, thereby raising overall healthcare costs. Higher healthcare spending contributes to reducing catheter-related bloodstream infections by financing preventative actions, staff education, surveillance systems, and prompt medical care, ultimately enhancing patient results and decreasing overall expenses. For instance, the Centers for Medicare & Medicaid Services reported in December 2024 that U.S. health care expenditures rose by 7.5% in 2023, reaching $4.9 trillion, equivalent to approximately $14,570 per person. Consequently, the escalating healthcare expenditure is fostering the growth of the catheter-related bloodstream infection market.

What Are The Main Segments Within The Catheter-Related Bloodstream Infection Market Segment Structure?

The catheter-related bloodstream infection market covered in this report is segmented –

1) By Treatment: Antibiotic Lock Therapy, Anti-Microbial Agents

2) By Source Of Infection Or Causative Agents: Staphylococcus Aureus, Acinetobacter Baumannii, Escherichia Coli (E. Coli), Klebsiella Pneumoniae (K. Pneumonia), Candida Species (Candida Sp.), Pseudomonas Aeruginosa (P. Aeruginosa), Other Source Of Infection Or Causative Agents

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Antibiotic Lock Therapy: Catheter Lock Solutions (Antibiotic-based), Combination Antibiotic Lock Therapy

2) By Anti-Microbial Agents: Antibiotics, Antifungal Agents, Antiseptic Agents

Which Trends Are Influencing Demand In The Catheter-Related Bloodstream Infection Market?

Leading companies in the catheter-related bloodstream infection market are developing innovative catheter lock solutions to enhance infection prevention and improve patient outcomes. A catheter lock solution is a liquid introduced into a catheter to prevent infections and maintain its patency between uses. For instance, in November 2023, CorMedix Inc., a US-based biopharmaceutical company focused on developing and commercializing therapeutic products, received US Food and Drug Administration approval for DefenCath (taurolidine and heparin) catheter lock solution for adult patients with kidney failure undergoing chronic hemodialysis via central venous catheter (CVC). This antimicrobial and antifungal solution is designed to reduce catheter-related bloodstream infections (CRBSIs), combining heparin for anticoagulation with taurolidine’s broad-spectrum antimicrobial properties.

Who Are The Companies Participating In The Catheter-Related Bloodstream Infection Market?

Major companies operating in the catheter-related bloodstream infection market are Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, 3M Company, Eli Lilly and Company, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company, Viatris Inc., B. Braun Medical Inc., Aurobindo Pharma Limited, Lupin Ltd., Xellia Pharmaceuticals Ltd., SteriMax Inc., Bactiguard AB, Hetero Healthcare Ltd., TauroPharm GmbH, Advacare Pharma, Citus Pharmaceuticals Inc., CorMedix Inc., JoinHub Pharma LLP, IntegraDose Compounding Services LLC

Get The Full Catheter-Related Bloodstream Infection Market Report:

https://www.thebusinessresearchcompany.com/report/catheter-related-bloodstream-infection-global-market-report

Which Region Dominates The Catheter-Related Bloodstream Infection Market By Market Share?

North America was the largest region in the catheter-related bloodstream infection market in 2025. The regions covered in the catheter-related bloodstream infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Catheter-Related Bloodstream Infection Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/catheter-related-bloodstream-infection-global-market-report

Browse Through More Reports Similar to the Global Catheter-Related Bloodstream Infection Market 2026, By The Business Research Company

Catheters Market Report 2026

https://www.thebusinessresearchcompany.com/report/catheters-global-market-report

Diagnostic Catheters Market Report 2026

https://www.thebusinessresearchcompany.com/report/diagnostic-catheters-global-market-report

Pediatric Catheter Market Report 2026

https://www.thebusinessresearchcompany.com/report/pediatric-catheter-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Catheter-Related Bloodstream Infection Market Grow Between 2026 And 2030?

The catheter-related bloodstream infection market has seen substantial growth in recent years. It is anticipated to expand from $1.62 billion in 2025 to $1.71 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.0%. This market’s past expansion can be attributed to the increased deployment of central venous catheters, a growing prevalence of hospital-acquired infections, the implementation of antibiotic lock therapy, the enlargement of intensive care facilities, and enhanced clinical understanding of crbsi.

The catheter-related bloodstream infection market size is projected to experience robust expansion in the coming years. This market is set to reach $2.11 billion in 2030, growing at a compound annual growth rate (CAGR) of 5.3%. The forecasted growth can be attributed to various factors such as increasing investments in infection prevention protocols, a rising demand for antimicrobial resistance management, the expansion of hospital infection control programs, a growing adoption of combination therapies, and advancements in diagnostic technologies. Significant trends within the forecast period include a greater use of advanced antimicrobial lock solutions, increasing adoption of infection surveillance programs, a heightened focus on preventing hospital-acquired infections, the proliferation of combination antimicrobial therapies, and an enhanced emphasis on early diagnosis and intervention.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/catheter-related-bloodstream-infection-global-market-report

Which Factors Are Influencing The Growth Of The Catheter-Related Bloodstream Infection Market?

The increasing occurrence of hospital-acquired infections is anticipated to boost the expansion of the catheter-related bloodstream infection market. HAIs are infections contracted by patients in healthcare settings while receiving treatment for other ailments, typically emerging 48 hours or more after admission. Factors like antimicrobial resistance, insufficient infection control, and patient vulnerability contribute to the rise in these infections. Catheter-related bloodstream infections are a major component of HAIs because of their invasive nature and potential for microbial growth, presenting risks to individuals with catheters. For example, the National Library of Medicine reported in September 2025 that in 2024, antimicrobial-resistant organisms constituted 6.6% of infections. Approximately one-third of healthcare-associated infections were associated with medical devices, and the incidence of central line-associated bloodstream infections surged to 0.4%. Consequently, the increasing incidence of hospital-acquired infections will fuel the growth of the catheter-related bloodstream infection market. The expansion of the catheter-related bloodstream infection market is anticipated to be driven by increasing healthcare expenditure. Healthcare expenditure signifies the total financial investment made by individuals, organizations, or governments towards the prevention, treatment, and management of health conditions. This spending is growing due to progress in medical technology, where advanced diagnostic tools, treatments, and innovative therapies often entail higher expenses, thereby raising overall healthcare costs. Higher healthcare spending contributes to reducing catheter-related bloodstream infections by financing preventative actions, staff education, surveillance systems, and prompt medical care, ultimately enhancing patient results and decreasing overall expenses. For instance, the Centers for Medicare & Medicaid Services reported in December 2024 that U.S. health care expenditures rose by 7.5% in 2023, reaching $4.9 trillion, equivalent to approximately $14,570 per person. Consequently, the escalating healthcare expenditure is fostering the growth of the catheter-related bloodstream infection market.

What Are The Main Segments Within The Catheter-Related Bloodstream Infection Market Segment Structure?

The catheter-related bloodstream infection market covered in this report is segmented –

1) By Treatment: Antibiotic Lock Therapy, Anti-Microbial Agents

2) By Source Of Infection Or Causative Agents: Staphylococcus Aureus, Acinetobacter Baumannii, Escherichia Coli (E. Coli), Klebsiella Pneumoniae (K. Pneumonia), Candida Species (Candida Sp.), Pseudomonas Aeruginosa (P. Aeruginosa), Other Source Of Infection Or Causative Agents

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Antibiotic Lock Therapy: Catheter Lock Solutions (Antibiotic-based), Combination Antibiotic Lock Therapy

2) By Anti-Microbial Agents: Antibiotics, Antifungal Agents, Antiseptic Agents

Which Trends Are Influencing Demand In The Catheter-Related Bloodstream Infection Market?

Leading companies in the catheter-related bloodstream infection market are developing innovative catheter lock solutions to enhance infection prevention and improve patient outcomes. A catheter lock solution is a liquid introduced into a catheter to prevent infections and maintain its patency between uses. For instance, in November 2023, CorMedix Inc., a US-based biopharmaceutical company focused on developing and commercializing therapeutic products, received US Food and Drug Administration approval for DefenCath (taurolidine and heparin) catheter lock solution for adult patients with kidney failure undergoing chronic hemodialysis via central venous catheter (CVC). This antimicrobial and antifungal solution is designed to reduce catheter-related bloodstream infections (CRBSIs), combining heparin for anticoagulation with taurolidine’s broad-spectrum antimicrobial properties.

Who Are The Companies Participating In The Catheter-Related Bloodstream Infection Market?

Major companies operating in the catheter-related bloodstream infection market are Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, 3M Company, Eli Lilly and Company, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company, Viatris Inc., B. Braun Medical Inc., Aurobindo Pharma Limited, Lupin Ltd., Xellia Pharmaceuticals Ltd., SteriMax Inc., Bactiguard AB, Hetero Healthcare Ltd., TauroPharm GmbH, Advacare Pharma, Citus Pharmaceuticals Inc., CorMedix Inc., JoinHub Pharma LLP, IntegraDose Compounding Services LLC

Get The Full Catheter-Related Bloodstream Infection Market Report:

https://www.thebusinessresearchcompany.com/report/catheter-related-bloodstream-infection-global-market-report

Which Region Dominates The Catheter-Related Bloodstream Infection Market By Market Share?

North America was the largest region in the catheter-related bloodstream infection market in 2025. The regions covered in the catheter-related bloodstream infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Catheter-Related Bloodstream Infection Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/catheter-related-bloodstream-infection-global-market-report

Browse Through More Reports Similar to the Global Catheter-Related Bloodstream Infection Market 2026, By The Business Research Company

Catheters Market Report 2026

https://www.thebusinessresearchcompany.com/report/catheters-global-market-report

Diagnostic Catheters Market Report 2026

https://www.thebusinessresearchcompany.com/report/diagnostic-catheters-global-market-report

Pediatric Catheter Market Report 2026

https://www.thebusinessresearchcompany.com/report/pediatric-catheter-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Catheter-Related Bloodstream Infection Market In 2026 And What Value Is Projected For 2030?

The catheter-related bloodstream infection market size has demonstrated robust expansion in recent years. It is anticipated to expand from $1.62 billion in 2025 to $1.71 billion in 2026, registering a compound annual growth rate (CAGR) of 6.0%. This historical growth can be attributed to factors such as the increased deployment of central venous catheters, a rising occurrence of hospital-acquired infections, the adoption of antibiotic lock therapy, the expansion of intensive care units, and enhanced clinical awareness of CRBSI.

The catheter-related bloodstream infection market size is projected to experience robust expansion over the upcoming years. This market is anticipated to reach $2.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This expansion during the projection period stems from heightened investments in protocols for infection prevention, an escalating need for antimicrobial resistance management, the broadening of hospital infection control initiatives, increasing embrace of combination therapies, and innovations in diagnostic technologies. Key trends anticipated within the forecast timeframe encompass the wider application of sophisticated antimicrobial lock solutions, the expanding implementation of infection surveillance programs, a heightened emphasis on preventing hospital-acquired infections, the proliferation of combination antimicrobial therapies, and a greater focus on timely diagnosis and intervention.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16646&type=smp

What Drivers Are Influencing The Catheter-Related Bloodstream Infection Market?

The expanding incidence of hospital-acquired infections is anticipated to boost the catheter-related bloodstream infection market in the coming years. Hospital-acquired infections (HAIs) are infections contracted by patients during medical treatment in a healthcare environment, typically appearing at least 48 hours post-admission. The rise in these infections stems from factors like antimicrobial resistance, insufficient infection control protocols, and patient vulnerability. Catheter-related bloodstream infections significantly contribute to HAIs because they are invasive and prone to microbial growth, endangering individuals with implanted catheters. For example, data from September 2025, cited by the US-based National Library of Medicine, indicated that in 2024, antimicrobial-resistant organisms (AROs) constituted 6.6% of infections. Additionally, approximately one-third of healthcare-associated infections (HAIs) were associated with medical devices, and central line-associated bloodstream infections (CLABSIs) saw their prevalence double to 0.4%. Consequently, the growing frequency of hospital-acquired infections will fuel the expansion of the catheter-related bloodstream infection market.

What Are The Key Segments Of The Catheter-Related Bloodstream Infection Market?

The catheter-related bloodstream infection market covered in this report is segmented –

1) By Treatment: Antibiotic Lock Therapy, Anti-Microbial Agents

2) By Source Of Infection Or Causative Agents: Staphylococcus Aureus, Acinetobacter Baumannii, Escherichia Coli (E. Coli), Klebsiella Pneumoniae (K. Pneumonia), Candida Species (Candida Sp.), Pseudomonas Aeruginosa (P. Aeruginosa), Other Source Of Infection Or Causative Agents

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Antibiotic Lock Therapy: Catheter Lock Solutions (Antibiotic-based), Combination Antibiotic Lock Therapy

2) By Anti-Microbial Agents: Antibiotics, Antifungal Agents, Antiseptic Agents

What Industry Trends Are Redefining The Catheter-Related Bloodstream Infection Market?

Leading companies in the catheter-related bloodstream infection market are creating advanced catheter lock solutions to improve infection prevention and patient results. A catheter lock solution is a fluid inserted into a catheter to deter infections and keep the catheter open between uses. For instance, in November 2023, CorMedix Inc., a US-based biopharmaceutical company concentrating on the development and commercialization of therapeutic products, obtained US Food and Drug Administration approval for DefenCath (taurolidine and heparin) catheter lock solution, designed for adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). This antimicrobial and antifungal solution is specifically engineered to lessen catheter-related bloodstream infections (CRBSIs), by merging heparin for anticoagulation with taurolidine’s extensive antimicrobial qualities.

Who Are The Leading Companies Operating In The Catheter-Related Bloodstream Infection Market?

Major companies operating in the catheter-related bloodstream infection market are Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, 3M Company, Eli Lilly and Company, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company, Viatris Inc., B. Braun Medical Inc., Aurobindo Pharma Limited, Lupin Ltd., Xellia Pharmaceuticals Ltd., SteriMax Inc., Bactiguard AB, Hetero Healthcare Ltd., TauroPharm GmbH, Advacare Pharma, Citus Pharmaceuticals Inc., CorMedix Inc., JoinHub Pharma LLP, IntegraDose Compounding Services LLC

Read the full catheter-related bloodstream infection market report here:

https://www.thebusinessresearchcompany.com/report/catheter-related-bloodstream-infection-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Catheter-Related Bloodstream Infection Market?

North America was the largest region in the catheter-related bloodstream infection market in 2025. The regions covered in the catheter-related bloodstream infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Catheter-Related Bloodstream Infection Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16646&type=smp

Browse Through More Reports Similar to the Global Catheter-Related Bloodstream Infection Market 2026, By The Business Research Company

Phospholipid Global Market Report

https://www.thebusinessresearchcompany.com/report/phospholipid-global-market-report

Lecithin And Phospholipids Global Market Report

https://www.thebusinessresearchcompany.com/report/lecithin-and-phospholipids-global-market-report

Hypolipidemics Global Market Report

https://www.thebusinessresearchcompany.com/report/hypolipidemics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Catheter-Related Bloodstream Infection Market In 2026 And What Value Is Projected For 2030?

The catheter-related bloodstream infection market size has demonstrated robust expansion in recent years. It is anticipated to expand from $1.62 billion in 2025 to $1.71 billion in 2026, registering a compound annual growth rate (CAGR) of 6.0%. This historical growth can be attributed to factors such as the increased deployment of central venous catheters, a rising occurrence of hospital-acquired infections, the adoption of antibiotic lock therapy, the expansion of intensive care units, and enhanced clinical awareness of CRBSI.

The catheter-related bloodstream infection market size is projected to experience robust expansion over the upcoming years. This market is anticipated to reach $2.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This expansion during the projection period stems from heightened investments in protocols for infection prevention, an escalating need for antimicrobial resistance management, the broadening of hospital infection control initiatives, increasing embrace of combination therapies, and innovations in diagnostic technologies. Key trends anticipated within the forecast timeframe encompass the wider application of sophisticated antimicrobial lock solutions, the expanding implementation of infection surveillance programs, a heightened emphasis on preventing hospital-acquired infections, the proliferation of combination antimicrobial therapies, and a greater focus on timely diagnosis and intervention.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16646&type=smp

What Drivers Are Influencing The Catheter-Related Bloodstream Infection Market?

The expanding incidence of hospital-acquired infections is anticipated to boost the catheter-related bloodstream infection market in the coming years. Hospital-acquired infections (HAIs) are infections contracted by patients during medical treatment in a healthcare environment, typically appearing at least 48 hours post-admission. The rise in these infections stems from factors like antimicrobial resistance, insufficient infection control protocols, and patient vulnerability. Catheter-related bloodstream infections significantly contribute to HAIs because they are invasive and prone to microbial growth, endangering individuals with implanted catheters. For example, data from September 2025, cited by the US-based National Library of Medicine, indicated that in 2024, antimicrobial-resistant organisms (AROs) constituted 6.6% of infections. Additionally, approximately one-third of healthcare-associated infections (HAIs) were associated with medical devices, and central line-associated bloodstream infections (CLABSIs) saw their prevalence double to 0.4%. Consequently, the growing frequency of hospital-acquired infections will fuel the expansion of the catheter-related bloodstream infection market.

What Are The Key Segments Of The Catheter-Related Bloodstream Infection Market?

The catheter-related bloodstream infection market covered in this report is segmented –

1) By Treatment: Antibiotic Lock Therapy, Anti-Microbial Agents

2) By Source Of Infection Or Causative Agents: Staphylococcus Aureus, Acinetobacter Baumannii, Escherichia Coli (E. Coli), Klebsiella Pneumoniae (K. Pneumonia), Candida Species (Candida Sp.), Pseudomonas Aeruginosa (P. Aeruginosa), Other Source Of Infection Or Causative Agents

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Antibiotic Lock Therapy: Catheter Lock Solutions (Antibiotic-based), Combination Antibiotic Lock Therapy

2) By Anti-Microbial Agents: Antibiotics, Antifungal Agents, Antiseptic Agents

What Industry Trends Are Redefining The Catheter-Related Bloodstream Infection Market?

Leading companies in the catheter-related bloodstream infection market are creating advanced catheter lock solutions to improve infection prevention and patient results. A catheter lock solution is a fluid inserted into a catheter to deter infections and keep the catheter open between uses. For instance, in November 2023, CorMedix Inc., a US-based biopharmaceutical company concentrating on the development and commercialization of therapeutic products, obtained US Food and Drug Administration approval for DefenCath (taurolidine and heparin) catheter lock solution, designed for adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). This antimicrobial and antifungal solution is specifically engineered to lessen catheter-related bloodstream infections (CRBSIs), by merging heparin for anticoagulation with taurolidine’s extensive antimicrobial qualities.

Who Are The Leading Companies Operating In The Catheter-Related Bloodstream Infection Market?

Major companies operating in the catheter-related bloodstream infection market are Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, 3M Company, Eli Lilly and Company, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company, Viatris Inc., B. Braun Medical Inc., Aurobindo Pharma Limited, Lupin Ltd., Xellia Pharmaceuticals Ltd., SteriMax Inc., Bactiguard AB, Hetero Healthcare Ltd., TauroPharm GmbH, Advacare Pharma, Citus Pharmaceuticals Inc., CorMedix Inc., JoinHub Pharma LLP, IntegraDose Compounding Services LLC

Read the full catheter-related bloodstream infection market report here:

https://www.thebusinessresearchcompany.com/report/catheter-related-bloodstream-infection-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Catheter-Related Bloodstream Infection Market?

North America was the largest region in the catheter-related bloodstream infection market in 2025. The regions covered in the catheter-related bloodstream infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Catheter-Related Bloodstream Infection Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16646&type=smp

Browse Through More Reports Similar to the Global Catheter-Related Bloodstream Infection Market 2026, By The Business Research Company

Phospholipid Global Market Report

https://www.thebusinessresearchcompany.com/report/phospholipid-global-market-report

Lecithin And Phospholipids Global Market Report

https://www.thebusinessresearchcompany.com/report/lecithin-and-phospholipids-global-market-report

Hypolipidemics Global Market Report

https://www.thebusinessresearchcompany.com/report/hypolipidemics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Catheter-Related Bloodstream Infection Market In 2026 And What Value Is Projected For 2030?

The catheter-related bloodstream infection market size has demonstrated robust expansion in recent years. It is anticipated to expand from $1.62 billion in 2025 to $1.71 billion in 2026, registering a compound annual growth rate (CAGR) of 6.0%. This historical growth can be attributed to factors such as the increased deployment of central venous catheters, a rising occurrence of hospital-acquired infections, the adoption of antibiotic lock therapy, the expansion of intensive care units, and enhanced clinical awareness of CRBSI.

The catheter-related bloodstream infection market size is projected to experience robust expansion over the upcoming years. This market is anticipated to reach $2.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This expansion during the projection period stems from heightened investments in protocols for infection prevention, an escalating need for antimicrobial resistance management, the broadening of hospital infection control initiatives, increasing embrace of combination therapies, and innovations in diagnostic technologies. Key trends anticipated within the forecast timeframe encompass the wider application of sophisticated antimicrobial lock solutions, the expanding implementation of infection surveillance programs, a heightened emphasis on preventing hospital-acquired infections, the proliferation of combination antimicrobial therapies, and a greater focus on timely diagnosis and intervention.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16646&type=smp

What Drivers Are Influencing The Catheter-Related Bloodstream Infection Market?

The expanding incidence of hospital-acquired infections is anticipated to boost the catheter-related bloodstream infection market in the coming years. Hospital-acquired infections (HAIs) are infections contracted by patients during medical treatment in a healthcare environment, typically appearing at least 48 hours post-admission. The rise in these infections stems from factors like antimicrobial resistance, insufficient infection control protocols, and patient vulnerability. Catheter-related bloodstream infections significantly contribute to HAIs because they are invasive and prone to microbial growth, endangering individuals with implanted catheters. For example, data from September 2025, cited by the US-based National Library of Medicine, indicated that in 2024, antimicrobial-resistant organisms (AROs) constituted 6.6% of infections. Additionally, approximately one-third of healthcare-associated infections (HAIs) were associated with medical devices, and central line-associated bloodstream infections (CLABSIs) saw their prevalence double to 0.4%. Consequently, the growing frequency of hospital-acquired infections will fuel the expansion of the catheter-related bloodstream infection market.

What Are The Key Segments Of The Catheter-Related Bloodstream Infection Market?

The catheter-related bloodstream infection market covered in this report is segmented –

1) By Treatment: Antibiotic Lock Therapy, Anti-Microbial Agents

2) By Source Of Infection Or Causative Agents: Staphylococcus Aureus, Acinetobacter Baumannii, Escherichia Coli (E. Coli), Klebsiella Pneumoniae (K. Pneumonia), Candida Species (Candida Sp.), Pseudomonas Aeruginosa (P. Aeruginosa), Other Source Of Infection Or Causative Agents

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

Subsegments:

1) By Antibiotic Lock Therapy: Catheter Lock Solutions (Antibiotic-based), Combination Antibiotic Lock Therapy

2) By Anti-Microbial Agents: Antibiotics, Antifungal Agents, Antiseptic Agents

What Industry Trends Are Redefining The Catheter-Related Bloodstream Infection Market?

Leading companies in the catheter-related bloodstream infection market are creating advanced catheter lock solutions to improve infection prevention and patient results. A catheter lock solution is a fluid inserted into a catheter to deter infections and keep the catheter open between uses. For instance, in November 2023, CorMedix Inc., a US-based biopharmaceutical company concentrating on the development and commercialization of therapeutic products, obtained US Food and Drug Administration approval for DefenCath (taurolidine and heparin) catheter lock solution, designed for adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). This antimicrobial and antifungal solution is specifically engineered to lessen catheter-related bloodstream infections (CRBSIs), by merging heparin for anticoagulation with taurolidine’s extensive antimicrobial qualities.

Who Are The Leading Companies Operating In The Catheter-Related Bloodstream Infection Market?

Major companies operating in the catheter-related bloodstream infection market are Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, 3M Company, Eli Lilly and Company, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company, Viatris Inc., B. Braun Medical Inc., Aurobindo Pharma Limited, Lupin Ltd., Xellia Pharmaceuticals Ltd., SteriMax Inc., Bactiguard AB, Hetero Healthcare Ltd., TauroPharm GmbH, Advacare Pharma, Citus Pharmaceuticals Inc., CorMedix Inc., JoinHub Pharma LLP, IntegraDose Compounding Services LLC

Read the full catheter-related bloodstream infection market report here:

https://www.thebusinessresearchcompany.com/report/catheter-related-bloodstream-infection-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Catheter-Related Bloodstream Infection Market?

North America was the largest region in the catheter-related bloodstream infection market in 2025. The regions covered in the catheter-related bloodstream infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Catheter-Related Bloodstream Infection Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16646&type=smp

Browse Through More Reports Similar to the Global Catheter-Related Bloodstream Infection Market 2026, By The Business Research Company

Phospholipid Global Market Report

https://www.thebusinessresearchcompany.com/report/phospholipid-global-market-report

Lecithin And Phospholipids Global Market Report

https://www.thebusinessresearchcompany.com/report/lecithin-and-phospholipids-global-market-report

Hypolipidemics Global Market Report

https://www.thebusinessresearchcompany.com/report/hypolipidemics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model